Free Trial
NASDAQ:JSPRW

Jasper Therapeutics (JSPRW) Stock Price, News & Analysis

$0.10 -0.01 (-10.56%)
As of 04/24/2025 09:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Jasper Therapeutics Stock (NASDAQ:JSPRW)

Key Stats

Today's Range
$0.06
$0.10
50-Day Range
$0.08
$0.15
52-Week Range
$0.06
$0.25
Volume
5,900 shs
Average Volume
7,227 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Receive JSPRW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JSPRW Stock News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Jasper Therapeutics (JSPR) Gets a Buy from UBS
Jasper Therapeutics (JSPR) Receives a Buy from Credit Suisse
See More Headlines

JSPRW Stock Analysis - Frequently Asked Questions

Jasper Therapeutics' stock was trading at $0.2096 at the beginning of 2025. Since then, JSPRW shares have decreased by 53.1% and is now trading at $0.0982.
View the best growth stocks for 2025 here
.

Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:JSPRW
Web
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:JSPRW) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners